Company Overview and News

 
Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug

2018-01-14 seekingalpha
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US. The funds will underwrite Phase III development of its GKA product and commercialization. Ultimately, Hua hopes dorzagliatin will generate annual revenues of $3 billion, a 15% slice of the China type 2 diabetes market, once the drug is approved.

 
LifeTech kündigt den Beginn einer Anwendungsbeobachtungsstudie des LAmbre (TM) LAA-Verschlusssystems an

2017-07-03 prnewswire
FRANKFURT, Deutschland, 3. Juli, 2017 /PRNewswire/ -- Am 30. Juni kündigte LifeTech Scientific Corporation (Börsensymbol: 1302.HK) auf dem Congenital and Structural Intervention Congress (CSI) 2017 in Frankfurt den Beginn einer 3-jährigen, weltweiten Anwendungsbeobachtungsstudie (PMS) des LAmbreTM Verschlusssystems für das linke Vorhofohr (LAA) an. In die Studie sollen mehr als 500 Patienten aus ca.

 
Inferior Vena Cava (IVC) Filters Market (Retrievable and Permanent) by Applications and Vendors Analysed at ReportsnReports.com

2017-05-19 prnewswire
The Global Inferior Vena Cava (IVC) Filters Market by Manufacturers, Countries, Type and Application, Forecast to 2022 report focuses on the Inferior Vena Cava (IVC) Filters in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

 
Global Left Atrial Appendage Closure Market 2017-2021

2017-03-08 prnewswire
LONDON, March 7, 2017 /PRNewswire/ -- About Left Atrial Appendage Closure Download the full report: https://www.reportbuyer.com/product/4611095/ Atrial fibrillation is one of the most common types of arrhythmia and is characterized by fast and irregular heart rhythms. The atria of patients suffering from the disease do not function properly. Atrial fibrillation can cause chest pain, heart failure, or stroke.

 
LifeTech annonce la certification CE pour le système LAmbreTM de fermeture de l'appendice auriculaire gauche

2016-06-16 prnewswire
LONDRES, 16 juin 2016 /PRNewswire/ -- LifeTech (1302.HK) a obtenu, le 15 juin 2016, la certification CE pour son système de fermeture de l'appendice auriculaire gauche (AAG) LAmbreTM. Il s'agit de la première certification CE d'un système de fermeture de l'AAG provenant de Chine.

 
LifeTech kündigt CE-Kennzeichnung für LAmbre(TM) LAA-Verschlusssystem an

2016-06-16 prnewswire
LONDON, 16. Juni 2016 /PRNewswire/ -- LifeTech (1302.HK) erhielt am 15. Juni 2016 für sein LAmbreTM Verschlusssystem für das linke Vorhofohr (LAA) die Zulassung für das CE-Zeichen. Dies ist das erste LAA-Verschlusssystem mit CE-Kennzeichnung aus China.

 
Aortic Endografts Market: 2016 Edition - The Global Aortic Endografts Market Was Estimated at $1.8 Billion in 2015

2016-02-25 prnewswire
DUBLIN, February 25, 2016 /PRNewswire/ -- Research and Markets...

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...